Silo Pharma, Inc. (SILO) Form 8-K — Oct 14, 2026
$SILOForm 8-KItems 1.01, 3.02, 9.01Filed Oct 14, 2026, 4:30 PM ET0001213900-26-109457Original filing
Silo Pharma entered into an asset purchase agreement dated October 13, 2026 to acquire software and related intellectual property known as Reputation Endpoints from Larry King. Consideration is 150,000 unregistered shares of Silo common stock, issued under Section 4(a)(2), subject to a lock-up ending at the earlier of 12 months, a change in control, or company consent.
Key figures
- Offering Price
- purchase price payable in common stock, par value $0.0001 per share
- Shares Offered
- 150000
- Rep Survival Months
- 12
- Lockup period months
- 12
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.